GP
WVE icon

GSK plc’s Wave Life Sciences WVE Stock Holding History

GSK plc’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106M Hold
18,245,691
– – 17.6% 2
2026
Q1 		$132M Hold
18,245,691
– – 22.08% 2
2025
Q4 		$310M Buy
+18,245,691
New +$185M 38.82% 1

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $47.2M AUM 32.31% 1-Year Est. Return

GSK plc's WVE Position: Q2 2026 in Review

GSK plc held its Wave Life Sciences (WVE) position steady in Q2 2026 at 18,245,691 shares worth $106M. The position accounts for 17.6% of the portfolio, ranked #2.

GSK plc first reported a position in WVE in Q4 2025 and has held it in 3 quarters since. The position peaked at $310M in Q4 2025. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • GSK plc held 18,245,691 shares of Wave Life Sciences worth $106M as of Q2 2026.
  • GSK plc left its Wave Life Sciences share count unchanged in Q2 2026.
  • Wave Life Sciences made up 17.6% of GSK plc's portfolio in Q2 2026, its #2 holding.
  • GSK plc first reported a position in Wave Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • GSK plc's Wave Life Sciences position peaked at $310M in Q4 2025.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on GSK plc's 13F filing for Q2 2026, filed 13 Aug 2026.